At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 267 enrolled
Drug / intervention
GSK561679 +1 moredrug
Likely dose
GSK561679 350mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Efficacy of the CRF1 Antagonist GSK561679 in Women With Post-traumatic Stress Disorder
In Brief
A Phase 2 clinical trial evaluating GSK561679 and Placebo for Stress Disorders, Post-Traumatic. Completed, enrolled 267 participants across 4 sites.
Detailed Summary
This study will test the hypothesis of whether an antagonist at the corticotropin releasing factor type 1 (CRF1) receptor (i.e. GSK561679) is superior to placebo in reducing symptoms of post-traumatic stress disorder (PTSD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStress Disorders, Post-Traumatic
CountriesUnited States
CollaboratorsIcahn School of Medicine at Mount Sinai
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2009
Enrollment StartDec 2009
Primary CompletionAug 2014
TodayJul 2026
First PostedNov 25, 2009
Enrollment StartDec 1, 2009
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 16.6 years ago
Interventions
GSK561679drug
GSK561679, oral administration, 350mg/day, 6 week administration
Placebodrug
Matching placebo, oral administration, 1 pill/day for 6 weeks